Evidence map›Paper›PMID 37781692›Full record

ArticleFrontiers in pharmacology2023

Study of the mass balance, biotransformation and safety of [

Rupeng Shi, Yi Chai, Hao Feng, Lijun Xie, Lulu Zhang, Tianqi Zhong, Juan Chen, Peng Yan, Bei Zhu, Jun Zhao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Directions for analgesic development.Journal of anesthesia and translational medicine · 2024
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Rupeng Shi *Phase I Clinical Trial Unit, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yi Chai *Phase I Clinical Trial Unit, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Hao FengValue Pharmaceutical Services Co., Ltd., Nanjing, China.
Lijun XiePhase I Clinical Trial Unit, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Lulu ZhangDepartment of Clinical Pharmacology, School of Pharmacy, Nanjing Medical University, Nanjing, China.
Tianqi ZhongPhase I Clinical Trial Unit, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Juan ChenPhase I Clinical Trial Unit, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Peng YanNuclear Medicine Department, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Bei ZhuPhase I Clinical Trial Unit, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jun ZhaoPhase I Clinical Trial Unit, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chen ZhouPhase I Clinical Trial Unit, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jiangsu Province Hospital · CNNanjing Medical University · CNChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

mass balancemetabolismopioid receptor agonistspharmacokineticsradiolabel study

Identifiers

PMID37781692
PMCPMC10538116
OpenAlexW4386738332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.